Publication date: Jul 09, 2019
This post was originally published on this siteEHP-101, a cannabidiol-based experimental therapy for multiple sclerosis, was able to recover myelin in damaged nerve fibers and lessen neuroinflammation in a mouse model of MS, data show. In two other MS mouse models – the experimental autoimmune encephalomyelitis (EAE) model, and Theiler’s murine encephalitis virus-induced (TMEV) – EHP-101 was also seen to prevent inflammation and myelin loss both in the spinal cord and brain. The post Cannabidiol-based Oral Treatment Seen to Promote Remyelination in Mice, Trial Planned in MS Patients appeared first on Multiple Sclerosis News Today. The post Cannabidiol-based Oral Treatment Seen to Promote Remyelination in Mice, Trial Planned in MS Patients appeared first on BioNewsFeeds.
|disease||MESH||experimental autoimmune encephalomyelitis|
- Emerald Health Pharmaceuticals Demonstrates Repair of Nerve Damage Related to Multiple Sclerosis
- The role of fatty acid binding protein 7 in spinal cord astrocytes in a mouse model of experimental autoimmune encephalomyelitis.